Embeda morphine/naltrexone regulatory update

Pfizer disclosed in its 2Q14 earnings that FDA delayed by 3 months the PDUFA date for an sNDA seeking to expand the label of Embeda morphine/naltrexone to include data from abuse-deterrent studies. Th...